Pharmacokinetic considerations in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis

Orthopedics

Volumn 29, Issue 6, 2006, Pages 497-501

  Toma, Meredith B ^a   Smith, Kelly M ^a,b   Martin, Craig A ^a   Rapp, Robert P ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; FOLINIC ACID; GLYCYLGLYCINE; LINCOSAMIDE; LINEZOLID; MINOCYCLINE; RIFAMPICIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN;

ARTICLE; BONE MARROW SUPPRESSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BONE LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG PENETRATION; DRUG PROTEIN BINDING; HUMAN; LIVER FAILURE; LONG TERM CARE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NEUTROPENIA; NONHUMAN; OSTEOMYELITIS; PREDICTION; SURGICAL TECHNIQUE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33745603449     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20060601-11     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention. Antimicrobial Resistance in Healthcare Settings. Accessed February 22, 2006. Available at: http://www.cdc.gov/ncidod/dhqp/ar.html.
2. Lew DP, Waldvogel FA. Osteomyelitis. N Eng J Med. 1997; 336:999-1007.
3. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004; 32:470-485.
4. Mader JT, Shirtliff ME, Bergquist SC, Calhoun J. Antimicrobial treatment of chronic osteomyelitis. Clin Orthop. 1999; 360:47-65.
5. Micromedex. Micromedex Healthcare Series. Accessed February 10, 2006. Available at: http://mdx.mc.uky.edu/.
6. Wilson KJ, Mader JT. Concentrations of vancomycin in bone and serum of normal rabbits and those with osteomyelitis. Antimicrob Agents Chemother. 1984; 25:140-141.
7. Graziani AL, Lawson LA, Gibson GA, Steinberg MA, MacGregor RR. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother. 1988; 32:1320-1322.
8. Minocycline: Drug information. Accessed: March 17, 2006. Available at: http://www.utdol.com/utd/content/topic.do?topicKey=drug_l_z/ 168716&type=A&selectedTitle=1~35.
9. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004; 64:63-88.
10. Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis. 2005; 40:1429-1434.
11. Diekema DJ, Pfaller PM, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001; 32(suppl 2):S114-S132.
12. Clindamycin: Drug information. Accessed March 17, 2006. Available at: http://www.utdol.com/utd/content/topic.do?topicKey=drug_a_k/ 60665&type=A&selectedTitle=2~82.
13. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin Infect Dis. 2004; 38:864-870.
14. Norden CW, Shinners E, Niederriter K. Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus. J Infect Dis. 1986; 153:956-959.
15. Rodriguez W, Ross S, Khan W, McKay D, Moskowitz P. Clindamycin in the treatment of osteomyelitis in children: a report of 29 cases. Am J Dis Child. 1977; 131:1088-1093.
16. Smilack JD, Flittie WH, Williams TW Jr. Bone concentrations of antimicrobial agents after parenteral administration. Antimicrob Agents Chemother. 1976; 9:169-171.
17. Haas DW, McAndrew MP. Bacterial osteomyelitis in adults: Evolving considerations in diagnosis and treatment Am J Med. 1996; 101:550-561.
18. Martinez-Aguilar G, Hammerman WN, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J. 2003; 22:593-598.
19. Yeldandi V, Strodtman R, Lentino JR. In-vitro and in-vivo studies of trimethoprim-sulfamethoxazole against multiple resistant Staphylococcus aureus. J Antimicrob Chemother. 1988; 22:873-880.
20. Stein A, Bataille JF, Drancourt M, et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoptim-sulfamethoxazole). Antimicrob Agents Chemother. 1998; 42:3086-3091.
21. Treatment of community-acquired MRSA infections. Med Lett Drugs Ther. 2006; 48:13-14.
22. Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection. 2004; 32:8-14.
23. Broder KW, Moise PA, Schultz RO, Forrest A, Schentag JJ. Clinical experience with line-zolid in conjunction with wound coverage techniques for skin and soft-tissue infections and postoperative osteomyelitis. Ann Plast Surg. 2004; 52:85-90.
24. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of line-zolid: summary of clinical experience. Antimicrob Agents Chemother. 2002; 46:2723-2726.
25. Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother: 2005; 56:611-614.
26. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/ pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis. 2005; 52:165-171.
27. Tombs N. Tissue distribution of GAR-936, a broad-spectrum antibiotic, in male rats. Presented at the 39th ICAAC Program and Abstracts. September 26-29, 1999, San Francisco, Calif.
28. Daptomycin: Drug information. Accessed March 30, 2006. Available at: http://www.utdol.com/utd/content/topic.do?topicKey=drug_a_k/ 67089&type=A&selectedTitle=1~11.
29. Mader JT, Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 1989; 33:689-692.
30. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2005; 43:5285-5287.
31. Marty FM, Yeh WW, Wennersten CB, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol. 2006; 44:595-597.
32. Vikram HR, Havill NL, Koeth LM, Boyce JM. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol. 2005; 43:5384-5387.